Xolair (omalizumab) Letter of Medical Necessity
Xolair (omalizumab) prior authorization requires specific clinical and laboratory criteria including IgE level, weight, and prior controller therapy trial.
FDA-Approved Indications
- ● moderate-to-severe persistent allergic asthma
- ● chronic spontaneous urticaria
- ● nasal polyps
- ● IgE-mediated food allergy (allergic reaction reduction)
Why Xolair Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. IgE level not documented
- 2. Inhaled corticosteroid trial not documented
- 3. Weight-based dosing not specified
What to Include in a Xolair Letter of Medical Necessity
Document indication, baseline IgE level, weight, allergen sensitivity, prior ICS/LABA trial, exacerbation history, and FEV1 if applicable.
Key clinical evidence to cite:
- ✓ INNOVATE, EXTRA, ASTERIA, GLACIAL trials
Relevant guidelines:
- 📖 GINA Asthma Strategy
- 📖 AAAAI Urticaria Practice Parameter
Xolair Prior Authorization Criteria
Standard criteria across major US payers for Xolair. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Inhaled corticosteroid trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Xolair
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Xolair Prior Authorization FAQ
Why was my Xolair prior authorization denied?
The most common denial reasons for Xolair are: IgE level not documented; Inhaled corticosteroid trial not documented; Weight-based dosing not specified.
What should a Xolair Letter of Medical Necessity include?
Document indication, baseline IgE level, weight, allergen sensitivity, prior ICS/LABA trial, exacerbation history, and FEV1 if applicable.
Which payers cover Xolair?
Xolair is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.